Opinion|Videos|April 10, 2025
Optimal Strategies for Navigating Referral and Bridging Therapy for CAR T-Cell Therapy in R/R DLBCL Patients
Author(s)Rita Assi, MD , Girish Kunapareddy, MD
Experts discuss when a patient should be referred from community practice to an academic or specialized program, the factors influencing the choice and timing of bridging therapy before CAR T infusion, and how bridging therapy is coordinated between academic and community settings.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- At what point should a patient be referred from community practice to an academic or specialized program?
- What factors influence your choice and the timing of bridging therapy relative to planned CAR T infusion?
- How do you coordinate bridging therapy, and is it typically done in the academic or community setting in your clinical practice?
Advertisement
Related to this article
VS-7375 produced a responses previously treated metastatic pancreatic ductal adenocarcinoma.
SurVaxM missed the SURVIVE trial OS end point in newly diagnosed glioblastoma, whereas a subgroup of patients 65 or younger had significantly improved OS.
The resubmission follows a third complete response letter issued in July 2026 that cited manufacturing deficiencies rather than efficacy or safety concerns.
The FDA has approved atezolizumab in combination with chemotherapy for some patients with stage 3 colon cancer following surgery.
The FDA approved nogapendekin alfa inbakicept plus BCG for BCG-unresponsive NMIBC with high-grade papillary-only tumors.
The FDA set a PDUFA target action date of March 31, 2027, for tabelecleucel in relapsed or refractory EBV-positive post-transplant lymphoproliferative disease.
Experts in gynecologic oncology overview top research being presented at the 2026 ESMO Congress.
Matthew P. Goetz, MD, explores menopausal status, recurrence risk, and adjuvant CDK4/6 inhibitor selection in HR-positive breast cancer.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Nogapendekin Alfa Inbakicept Plus BCG for High-Grade, Papillary-Only BCG-Unresponsive NMIBC
2
Long-Term and Novel ADC Data Dominate Top Gynecologic Cancer Abstracts at ESMO 2026
3
FDA Accepts BLA Resubmission for Tabelecleucel in EBV+ Post-Transplant Lymphoproliferative Disease
4
SurVaxM Cancer Vaccine Shows Clinically Meaningful OS Signal in Newly Diagnosed Glioblastoma
5